---
title: miR-222 inhibits pathological cardiac hypertrophyand heart failure
date: '2023-12-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38084908/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231212170812&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: While miR-222 is necessary for physiological cardiac growth,
  it inhibits cardiac growth in response to pressure overload and reduces adverse
  remodeling and cardiac dysfunction. These findings support the model that physiological
  and pathological hypertrophy are fundamentally different. Further, they suggest
  miR-222 may hold promise as a therapeutic target in pathological cardiac hypertrophy
  and heart ...'
disable_comments: true
---
CONCLUSIONS: While miR-222 is necessary for physiological cardiac growth, it inhibits cardiac growth in response to pressure overload and reduces adverse remodeling and cardiac dysfunction. These findings support the model that physiological and pathological hypertrophy are fundamentally different. Further, they suggest miR-222 may hold promise as a therapeutic target in pathological cardiac hypertrophy and heart ...